Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

Authors:

Abstract
Introduction Intramuscular paromomycin monotherapy to treat visceral leishmaniasis (VL) has been shown to be effective for Indian patients, while a similar regimen resulted in lower efficacy in Eastern Africa, which could be related to differences in paromomycin pharmacokinetics. Methods Pharmacokinetic data were available from two randomized controlled trials in VL patients from Eastern Africa and India. African patients received intramuscular paromomycin monotherapy (20 mg/kg for 21 days) or combination therapy (15 mg/kg for 17 days) with sodium stibogluconate. Indian patients received paromomycin monotherapy (15 mg/kg for 21 days). A population pharmacokinetic model was developed for paromomycin in Eastern African and Indian VL patients. Results Seventy-four African patients (388 observations) and 528 Indian patients (1321 observations) were included in this pharmacokinetic analysis. A one-compartment model with first-order kinetics of absorption and elimination best described paromomycin in plasma. Bioavailability (relative standard error) was 1.17 (5.18%) times higher in Kenyan and Sudanese patients, and 2.46 (24.5%) times higher in Ethiopian patients, compared with Indian patients. Ethiopian patients had an approximately fourfold slower absorption rate constant of 0.446 h–1 (18.2%). Area under the plasma concentration-time curve for 24 h at steady-state (AUCτ,SS) for 15 mg/kg/day (median [interquartile range]) was higher in Kenya and Sudan (172.7 µg·h/mL [145.9–214.3]) and Ethiopia (230.1 µg·h/mL [146.3–591.2]) compared with India (97.26 µg·h/mL [80.83–123.4]). Conclusion The developed model provides detailed insight into the pharmacokinetic differences among Eastern African countries and India, however the resulting differences in paromomycin exposure do not seem to explain the geographical differences in paromomycin efficacy in the treatment of VL patients.
Funding Information
  • Médecins Sans Frontières
  • Drugs for Neglected Diseases initiative
  • Department for International Development
  • Médecins Sans Frontières/Doctors without Borders, International
  • Ministry of Foreign and European Affairs (MAEE), France; Region of Tuscany, Italy; République and Canton de Geneva, Switzerland
  • Medicor Foundation, Liechtenstein
  • Fondation Pro Victimis, Switzerland
  • Fondation André & Cyprien, Switzerland
  • Spanish Agency for International Development Cooperation (AECID), Spain
  • Swiss Agency for Development and Cooperation (SDC), Switzerland
  • Bill and Melinda Gates Foundation
  • Institute for OneWorld Health
  • Special Program for Research and Training in Tropical Diseases (TDR) of the United Nations Development Program
  • World Health Organization
  • Second European and Developing Countries Clinical Trials Partnership Programme (RIA2016S1635)
  • ZonMw/Dutch Research Council (91617140)

This publication has 26 references indexed in Scilit: